3/6
10:58 am
fate
Rating for FATE
Medium
Report
Rating for FATE
3/6
09:20 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
High
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
3/6
09:20 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
High
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
3/6
09:08 am
fate
Rating for FATE
High
Report
Rating for FATE
3/6
09:08 am
fate
Rating for FATE
High
Report
Rating for FATE
3/6
08:58 am
fate
Rating for FATE
High
Report
Rating for FATE
3/6
08:58 am
fate
Rating for FATE
High
Report
Rating for FATE
3/6
08:12 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
High
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
3/6
06:55 am
fate
Rating for FATE
Medium
Report
Rating for FATE
3/6
06:55 am
fate
Rating for FATE
Medium
Report
Rating for FATE